Dr Terri Wood Jerkins, MD | |
2010 Church St, Suite 410, Nashville, TN 37203-2012 | |
(615) 329-5029 | |
(615) 329-5081 |
Full Name | Dr Terri Wood Jerkins |
---|---|
Gender | Female |
Speciality | Endocrinology |
Experience | 43 Years |
Location | 2010 Church St, Nashville, Tennessee |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538147319 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | MD14486 (Tennessee) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Williamson Medical Center | Franklin, TN | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr Terri Wood Jerkins, MD 2010 Church St, Suite 410, Nashville, TN 37203-2012 Ph: (615) 329-5029 | Dr Terri Wood Jerkins, MD 2010 Church St, Suite 410, Nashville, TN 37203-2012 Ph: (615) 329-5029 |
News Archive
Lung surgery patients who utilize a comprehensive, evidence-based enhanced recovery after surgery (ERAS) program require fewer opioid prescriptions when discharged and this effect was sustained over the 4-year study period, according to research presented today at the 18th Annual Perioperative and Critical Care Conference from The Society of Thoracic Surgeons.
Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).
The U.S. Department of Agriculture's National Institute of Food and Agriculture today announced $11 million in available funding for projects that mitigate antimicrobial resistance (AMR), a growing public health issue that affects more than 2 million people annually.
› Verified 6 days ago
Megan Desai, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4220 Harding Pike, Nashville, TN 37205 Phone: 615-222-6726 Fax: 615-222-3702 | |
Harrison Klause, Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
John N Bowers, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike Ste 500, Nashville, TN 37205 Phone: 629-255-2493 Fax: 629-255-4266 | |
Dr. Evan Zehr, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1161 21st Ave S, Nashville, TN 37232 Phone: 615-322-6943 | |
Spurthi N Bhatt, MD MPH Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Mr. Robert M Johnson, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2410 Patterson St, Suite 106, Nashville, TN 37203 Phone: 615-340-4611 Fax: 615-340-4658 | |
Mr. John E Anderson, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 400, Nashville, TN 37203 Phone: 615-342-5900 Fax: 615-342-5912 |